Supplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Tables S9-S17 showing mutivariate and bivariate analysis for ORR, CBR, PFS and OS
Fields of Study & Subjects
Breast Cancer Treatment Studies
Advanced Breast Cancer Therapies
Cancer Immunotherapy and Biomarkers
Publication details
- Publication date
- 1 April 2026
- Language
- EN